X

Trial Profile

A Phase I Study of Pyrotinib in Patients With HER2 Positive Advanced Breast Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 27 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pyrotinib (Primary)
Indications Advanced breast cancer; HER2 positive breast cancer
Focus Adverse reactions
Sponsors Jiangsu Hengrui Medicine Co.

Most Recent Events

07 Jun 2022 Results of pooled analysis from (NCT01937689,NCT02361112,NCT02422199,NCT03080805) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
07 Jun 2016 Planned primary completion date changed from 1 Sep 2015 to 1 Jul 2016.
12 Dec 2015 Status changed from active, no longer recruiting to completed, as per results presented at the 38th Annual San Antonio Breast Cancer Symposium.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com